exendin-4-oyl-L-cysteinamide, conjugated at Cys 40 via a 1-O-(3-{O'-[3-(3-maleimidopropanamido)propyl]polyethylene glycol-O-yl}propylaminocarbonyl)glycerol linker with two O-methylpoly(ethylene glycol) chains

Multiple Sclerosis

Johns Hopkins Universityprotein_peptidePhase 2Active

CCC

48/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 65/ 100

Competitive context

182 Active assets in the Multiple Sclerosis cohort.

Asset / Sponsor	Phase	Rating
Cladribine University Hospital, Strasbourg, France	Phase 4	BBB
Nabiximols Jazz Pharmaceuticals	Phase 4	BBB
Teriflunomide Sanofi	Phase 4	BBB
Fampridine MGH Institute of Health Professions	Phase 4	BBB
Ocrevus Polpharma Biologics International AG	Phase 4	BBB

View all 50 →

Same molecule, other indications

exendin-4-oyl-L-cysteinamide, conjugated at Cys 40 via a 1-O-(3-{O'-[3-(3-maleimidopropanamido)propyl]polyethylene glycol-O-yl}propylaminocarbonyl)glycerol linker with two O-methylpoly(ethylene glycol) chains is also rated in:

Parkinson diseaseDormant

CCC

Indicative ·

51 / 100

View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →